Long-term oncological follow-up after mold-based pulsed dose rate brachytherapy for early stage squamous cell carcinoma of the nasal vestibule: A single center experience of 68 patients over a 17-year period

W F Julius Scheurleer; Homan Dehnad; W Weibel Braunius; Luuk M Janssen; Bernard M Tijink; Gerben E Breimer; Ernst J Smid; Lot A Devriese; Remco de Bree; Mischa de Ridder; Johannes A Rijken

doi:10.1016/j.brachy.2022.11.009

Long-term oncological follow-up after mold-based pulsed dose rate brachytherapy for early stage squamous cell carcinoma of the nasal vestibule: A single center experience of 68 patients over a 17-year period

W F Julius Scheurleer^*, Homan Dehnad, W Weibel Braunius, Luuk M Janssen, Bernard M Tijink, Gerben E Breimer, Ernst J Smid, Lot A Devriese, Remco de Bree, Mischa de Ridder, Johannes A Rijken

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

3 Downloads (Pure)

Abstract

PURPOSE: Cancer of the nasal vestibule is a rare type of malignancy constituting less than one percent of all head and neck cancers. These tumors are typically diagnosed at an early stage. Both surgery and radiotherapy provide excellent oncological results, but esthetic results are better after radiotherapy. The aim of this study was to evaluate the long-term oncological follow-up after brachytherapy for early stage squamous cell carcinoma of the nasal vestibule.

METHODS AND MATERIALS: Retrospective analysis of patients with carcinoma of the nasal vestibule who were treated with primary brachytherapy in the Utrecht University Medical Center.

RESULTS: In this single center experience over a 17-year period 68 patients with early stage squamous cell carcinoma of the nasal vestibule were treated with brachytherapy. Two patients had lymph node metastases at first clinical presentation. Median follow-up duration was 46.5 months. Five-year locoregional recurrence-free survival, disease-specific survival, and overall survival were 91.1%, 96.1%, and 66.2%, respectively. All recurrences occurred within the first 3 years of follow-up.

CONCLUSIONS: Brachytherapy offers excellent oncological outcomes and is a safe and effective treatment for early stage carcinoma of the nasal vestibule. Recurrences typically occur within 3 years after treatment.

Original language	English
Pages (from-to)	221-230
Number of pages	10
Journal	Brachytherapy
Volume	22
Issue number	2
Early online date	18 Dec 2022
DOIs	https://doi.org/10.1016/j.brachy.2022.11.009
Publication status	Published - Mar 2023

Keywords

Brachytherapy
Nasal malignancies
Nasal vestibule
Squamous cell carcinoma

Access to Document

10.1016/j.brachy.2022.11.009Licence: CC BY

1-s2.0-S1538472122003828-mainFinal published version, 2.13 MBLicence: CC BY

Fingerprint

Dive into the research topics of 'Long-term oncological follow-up after mold-based pulsed dose rate brachytherapy for early stage squamous cell carcinoma of the nasal vestibule: A single center experience of 68 patients over a 17-year period'. Together they form a unique fingerprint.

Cite this

Scheurleer, W. F. J., Dehnad, H., Braunius, W. W., Janssen, L. M., Tijink, B. M., Breimer, G. E., Smid, E. J., Devriese, L. A., Bree, R. D., Ridder, M. D., & Rijken, J. A. (2023). Long-term oncological follow-up after mold-based pulsed dose rate brachytherapy for early stage squamous cell carcinoma of the nasal vestibule: A single center experience of 68 patients over a 17-year period. Brachytherapy, 22(2), 221-230. https://doi.org/10.1016/j.brachy.2022.11.009

@article{f449712c33c042a2b23e98150327acb4,

title = "Long-term oncological follow-up after mold-based pulsed dose rate brachytherapy for early stage squamous cell carcinoma of the nasal vestibule: A single center experience of 68 patients over a 17-year period",

abstract = "PURPOSE: Cancer of the nasal vestibule is a rare type of malignancy constituting less than one percent of all head and neck cancers. These tumors are typically diagnosed at an early stage. Both surgery and radiotherapy provide excellent oncological results, but esthetic results are better after radiotherapy. The aim of this study was to evaluate the long-term oncological follow-up after brachytherapy for early stage squamous cell carcinoma of the nasal vestibule.METHODS AND MATERIALS: Retrospective analysis of patients with carcinoma of the nasal vestibule who were treated with primary brachytherapy in the Utrecht University Medical Center.RESULTS: In this single center experience over a 17-year period 68 patients with early stage squamous cell carcinoma of the nasal vestibule were treated with brachytherapy. Two patients had lymph node metastases at first clinical presentation. Median follow-up duration was 46.5 months. Five-year locoregional recurrence-free survival, disease-specific survival, and overall survival were 91.1%, 96.1%, and 66.2%, respectively. All recurrences occurred within the first 3 years of follow-up.CONCLUSIONS: Brachytherapy offers excellent oncological outcomes and is a safe and effective treatment for early stage carcinoma of the nasal vestibule. Recurrences typically occur within 3 years after treatment.",

keywords = "Brachytherapy, Nasal malignancies, Nasal vestibule, Squamous cell carcinoma",

author = "Scheurleer, {W F Julius} and Homan Dehnad and Braunius, {W Weibel} and Janssen, {Luuk M} and Tijink, {Bernard M} and Breimer, {Gerben E} and Smid, {Ernst J} and Devriese, {Lot A} and Bree, {Remco de} and Ridder, {Mischa de} and Rijken, {Johannes A}",

note = "Funding Information: Disclosures: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Publisher Copyright: {\textcopyright} 2022 The Authors",

year = "2023",

month = mar,

doi = "10.1016/j.brachy.2022.11.009",

language = "English",

volume = "22",

pages = "221--230",

journal = "Brachytherapy",

issn = "1538-4721",

publisher = "Elsevier",

number = "2",

}

Scheurleer, WFJ, Dehnad, H, Braunius, WW, Janssen, LM, Tijink, BM, Breimer, GE, Smid, EJ, Devriese, LA, Bree, RD , Ridder, MD & Rijken, JA 2023, 'Long-term oncological follow-up after mold-based pulsed dose rate brachytherapy for early stage squamous cell carcinoma of the nasal vestibule: A single center experience of 68 patients over a 17-year period', Brachytherapy, vol. 22, no. 2, pp. 221-230. https://doi.org/10.1016/j.brachy.2022.11.009

Long-term oncological follow-up after mold-based pulsed dose rate brachytherapy for early stage squamous cell carcinoma of the nasal vestibule: A single center experience of 68 patients over a 17-year period. / Scheurleer, W F Julius; Dehnad, Homan; Braunius, W Weibel et al.
In: Brachytherapy, Vol. 22, No. 2, 03.2023, p. 221-230.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Long-term oncological follow-up after mold-based pulsed dose rate brachytherapy for early stage squamous cell carcinoma of the nasal vestibule

T2 - A single center experience of 68 patients over a 17-year period

AU - Scheurleer, W F Julius

AU - Dehnad, Homan

AU - Braunius, W Weibel

AU - Janssen, Luuk M

AU - Tijink, Bernard M

AU - Breimer, Gerben E

AU - Smid, Ernst J

AU - Devriese, Lot A

AU - Bree, Remco de

AU - Ridder, Mischa de

AU - Rijken, Johannes A

N1 - Funding Information: Disclosures: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Publisher Copyright: © 2022 The Authors

PY - 2023/3

Y1 - 2023/3

N2 - PURPOSE: Cancer of the nasal vestibule is a rare type of malignancy constituting less than one percent of all head and neck cancers. These tumors are typically diagnosed at an early stage. Both surgery and radiotherapy provide excellent oncological results, but esthetic results are better after radiotherapy. The aim of this study was to evaluate the long-term oncological follow-up after brachytherapy for early stage squamous cell carcinoma of the nasal vestibule.METHODS AND MATERIALS: Retrospective analysis of patients with carcinoma of the nasal vestibule who were treated with primary brachytherapy in the Utrecht University Medical Center.RESULTS: In this single center experience over a 17-year period 68 patients with early stage squamous cell carcinoma of the nasal vestibule were treated with brachytherapy. Two patients had lymph node metastases at first clinical presentation. Median follow-up duration was 46.5 months. Five-year locoregional recurrence-free survival, disease-specific survival, and overall survival were 91.1%, 96.1%, and 66.2%, respectively. All recurrences occurred within the first 3 years of follow-up.CONCLUSIONS: Brachytherapy offers excellent oncological outcomes and is a safe and effective treatment for early stage carcinoma of the nasal vestibule. Recurrences typically occur within 3 years after treatment.

AB - PURPOSE: Cancer of the nasal vestibule is a rare type of malignancy constituting less than one percent of all head and neck cancers. These tumors are typically diagnosed at an early stage. Both surgery and radiotherapy provide excellent oncological results, but esthetic results are better after radiotherapy. The aim of this study was to evaluate the long-term oncological follow-up after brachytherapy for early stage squamous cell carcinoma of the nasal vestibule.METHODS AND MATERIALS: Retrospective analysis of patients with carcinoma of the nasal vestibule who were treated with primary brachytherapy in the Utrecht University Medical Center.RESULTS: In this single center experience over a 17-year period 68 patients with early stage squamous cell carcinoma of the nasal vestibule were treated with brachytherapy. Two patients had lymph node metastases at first clinical presentation. Median follow-up duration was 46.5 months. Five-year locoregional recurrence-free survival, disease-specific survival, and overall survival were 91.1%, 96.1%, and 66.2%, respectively. All recurrences occurred within the first 3 years of follow-up.CONCLUSIONS: Brachytherapy offers excellent oncological outcomes and is a safe and effective treatment for early stage carcinoma of the nasal vestibule. Recurrences typically occur within 3 years after treatment.

KW - Brachytherapy

KW - Nasal malignancies

KW - Nasal vestibule

KW - Squamous cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85144323699&partnerID=8YFLogxK

U2 - 10.1016/j.brachy.2022.11.009

DO - 10.1016/j.brachy.2022.11.009

M3 - Article

C2 - 36539317

SN - 1538-4721

VL - 22

SP - 221

EP - 230

JO - Brachytherapy

JF - Brachytherapy

IS - 2

ER -

Scheurleer WFJ, Dehnad H, Braunius WW, Janssen LM, Tijink BM, Breimer GE et al. Long-term oncological follow-up after mold-based pulsed dose rate brachytherapy for early stage squamous cell carcinoma of the nasal vestibule: A single center experience of 68 patients over a 17-year period. Brachytherapy. 2023 Mar;22(2):221-230. Epub 2022 Dec 18. doi: 10.1016/j.brachy.2022.11.009

Long-term oncological follow-up after mold-based pulsed dose rate brachytherapy for early stage squamous cell carcinoma of the nasal vestibule: A single center experience of 68 patients over a 17-year period

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this